We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other best ...

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Discover how this crimson brew may lower blood pressure as effectively as medication while offering additional heart health ...

Brazilian researchers discover traditional fermented drink kefir significantly improves memory and cognitive function in ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

U.S. President Donald Trump plans to nominate Susan Monarez as director of the Centers for Disease Control and Prevention, ...